Statement of Deviation or Variation for the Quarter and Financial Year ended on March 31, 2026
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Orchid Pharma reported standalone revenue of Rs 81,133 lakhs for FY26, down 12% from Rs 92,193 lakhs in FY25. Standalone profit after tax fell 57% to Rs 4,521 lakhs while consolidated PAT dropped 79% to Rs 2,055 lakhs due to lower sales and higher costs. The auditor issued a qualified opinion on consolidated results because three US subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.) submitted unaudited financials. Key developments include acquisition of 100% global rights to Enmetazobactam (EXBLIFEP) from Allecra Therapeutics, setting up a new European subsidiary, and a pending merger with holding company Dhanuka Laboratories awaiting NCLT approval. Capital expenditure nearly tripled to Rs 38,358 lakhs, largely for the Jammu manufacturing facility.
The significant profit decline and qualified auditor opinion on consolidated results may concern investors, though the strategic acquisitions and ongoing expansion plans could support long-term growth. The company maintains positive operating cash flows despite heavy investments.